Inherited variation in immune genes and pathways and glioblastoma risk
- PMID: 20668009
- PMCID: PMC2950934
- DOI: 10.1093/carcin/bgq152
Inherited variation in immune genes and pathways and glioblastoma risk
Abstract
To determine whether inherited variations in immune function single-nucleotide polymorphisms (SNPs), genes or pathways affect glioblastoma risk, we analyzed data from recent genome-wide association studies in conjunction with predefined immune function genes and pathways. Gene and pathway analyses were conducted on two independent data sets using 6629 SNPs in 911 genes on 17 immune pathways from 525 glioblastoma cases and 602 controls from the University of California, San Francisco (UCSF) and a subset of 6029 SNPs in 893 genes from 531 cases and 1782 controls from MD Anderson (MDA). To further assess consistency of SNP-level associations, we also compared data from the UK (266 cases and 2482 controls) and the Mayo Clinic (114 cases and 111 controls). Although three correlated epidermal growth factor receptor (EGFR) SNPs were consistently associated with glioblastoma in all four data sets (Mantel-Haenzel P values = 1 × 10⁻⁵ to 4 × 10⁻³), independent replication is required as genome-wide significance was not attained. In gene-level analyses, eight immune function genes were significantly (minP < 0.05) associated with glioblastoma; the IL-2RA (CD25) cytokine gene had the smallest minP values in both UCSF (minP = 0.01) and MDA (minP = 0.001) data sets. The IL-2RA receptor is found on the surface of regulatory T cells potentially contributing to immunosuppression characteristic of the glioblastoma microenvironment. In pathway correlation analyses, cytokine signaling and adhesion-extravasation-migration pathways showed similar associations with glioblastoma risk in both MDA and UCSF data sets. Our findings represent the first systematic description of immune genes and pathways that characterize glioblastoma risk.
Figures


Similar articles
-
SSBP2 variants are associated with survival in glioblastoma patients.Clin Cancer Res. 2012 Jun 1;18(11):3154-62. doi: 10.1158/1078-0432.CCR-11-2778. Epub 2012 Apr 3. Clin Cancer Res. 2012. PMID: 22472174 Free PMC article.
-
Genetic variations in EGF and EGFR and glioblastoma outcome.Neuro Oncol. 2010 Aug;12(8):815-21. doi: 10.1093/neuonc/noq018. Epub 2010 Mar 2. Neuro Oncol. 2010. PMID: 20197289 Free PMC article.
-
Germline polymorphisms in myeloid-associated genes are not associated with survival in glioma patients.J Neurooncol. 2018 Jan;136(1):33-39. doi: 10.1007/s11060-017-2622-6. Epub 2017 Sep 30. J Neurooncol. 2018. PMID: 28965162 Free PMC article.
-
Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma.Front Immunol. 2020 Jul 17;11:1402. doi: 10.3389/fimmu.2020.01402. eCollection 2020. Front Immunol. 2020. PMID: 32765498 Free PMC article. Review.
-
Understanding the role of cytokines in Glioblastoma Multiforme pathogenesis.Cancer Lett. 2012 Mar 28;316(2):139-50. doi: 10.1016/j.canlet.2011.11.001. Epub 2011 Nov 7. Cancer Lett. 2012. PMID: 22075379 Review.
Cited by
-
Recent advances in the molecular understanding of glioblastoma.J Neurooncol. 2012 May;108(1):11-27. doi: 10.1007/s11060-011-0793-0. Epub 2012 Jan 20. J Neurooncol. 2012. PMID: 22270850 Free PMC article. Review.
-
Significance of GSTM1 and GSTT1 Gene Deletions in Glioma Patients in Polish Population: Pilot Study.Clin Med Insights Oncol. 2025 Apr 21;19:11795549251330712. doi: 10.1177/11795549251330712. eCollection 2025. Clin Med Insights Oncol. 2025. PMID: 40291839 Free PMC article.
-
Dissecting Molecular Features of Gliomas: Genetic Loci and Validated Biomarkers.Int J Mol Sci. 2020 Jan 20;21(2):685. doi: 10.3390/ijms21020685. Int J Mol Sci. 2020. PMID: 31968687 Free PMC article. Review.
-
Glioma.Nat Rev Dis Primers. 2024 May 9;10(1):33. doi: 10.1038/s41572-024-00516-y. Nat Rev Dis Primers. 2024. PMID: 38724526 Review.
-
The Influence of DNA Repair Genes and Prenatal Tobacco Exposure on Risk of Childhood Acute Lymphoblastic Leukemia: A Gene-Environment Interaction Study.Cancer Epidemiol Biomarkers Prev. 2025 Jan 9;34(1):100-107. doi: 10.1158/1055-9965.EPI-24-1037. Cancer Epidemiol Biomarkers Prev. 2025. PMID: 39495115 Free PMC article.
References
-
- Fisher JL, et al. Epidemiology of brain tumors. Neurol. Clin. 2007;25:867–890. vii. - PubMed
-
- Linos E, et al. Atopy and risk of brain tumors: a meta-analysis. J. Natl Cancer Inst. 2007;99:1544–1550. - PubMed
-
- Sivak-Sears N, et al. Case-control study of non-steroidal anti-inflammatory drug use and glioblastoma multiforme. Am. J. Epidemiol. 2004;159:1131–1139. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P50 CA108961/CA/NCI NIH HHS/United States
- 5R01 CA119215/CA/NCI NIH HHS/United States
- R25 CA112355/CA/NCI NIH HHS/United States
- P50 CA097257/CA/NCI NIH HHS/United States
- R01 CA070917/CA/NCI NIH HHS/United States
- P50CA097257/CA/NCI NIH HHS/United States
- WT_/Wellcome Trust/United Kingdom
- P30 CA15083/CA/NCI NIH HHS/United States
- R01 CA122163/CA/NCI NIH HHS/United States
- C1298/A8362/CRUK_/Cancer Research UK/United Kingdom
- R01 CA052689/CA/NCI NIH HHS/United States
- R25 CA 112355/CA/NCI NIH HHS/United States
- 5R01 CA070917/CA/NCI NIH HHS/United States
- R01CA122163/CA/NCI NIH HHS/United States
- P30 CA015083/CA/NCI NIH HHS/United States
- R01 CA119215/CA/NCI NIH HHS/United States
- R01CA52689/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous